Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
Background: Despite dual antiplatelet therapy, the rate of major adverse cardiovascular events (MACE) after percutaneous coronary angioplasty remains high. Studies have shown interindividual variations in response to clopidogrel. Furthermore, there is an apparent link between clinical outcomes and c...
Gespeichert in:
| Veröffentlicht in: | Journal of thrombosis and haemostasis 2007-08, Vol.5 (8), p.1630-1636 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1636 |
|---|---|
| container_issue | 8 |
| container_start_page | 1630 |
| container_title | Journal of thrombosis and haemostasis |
| container_volume | 5 |
| creator | BONELLO, L. PAGANELLI, F. ARPIN‐BORNET, M. AUQUIER, P. SAMPOL, J. DIGNAT‐GEORGE, F. BARRAGAN, P. CAMOIN‐JAU, L. |
| description | Background: Despite dual antiplatelet therapy, the rate of major adverse cardiovascular events (MACE) after percutaneous coronary angioplasty remains high. Studies have shown interindividual variations in response to clopidogrel. Furthermore, there is an apparent link between clinical outcomes and clopidogrel resistance. Objectives: To investigate the value of platelet reactivity index (PRI), assessed by vasodilator‐stimulated phosphoprotein (VASP) phosphorylation analysis, for predicting MACE after percutaneous coronary intervention (PCI) with stent implantation.Methods: A prospective monocentric study was performed on 144 patients undergoing PCI. PR was evaluated by VASP phosphorylation analysis 24 h after they received a 300‐mg loading dose of clopidogrel. MACE were recorded during a 6‐month follow‐up. Patients were divided into quintiles according to PRI, as assessed by VASP analysis. The receiver operating characteristic (ROC) curve served to determine the optimal cut‐off value of VASP analysis to detect MACE.Results: Of the 144 patients, 34% had stable angina pectoris, 40% silent ischemia, and 26% low‐risk non‐ST‐segment elevation acute coronary syndrome. During the follow‐up, 21 MACE were observed. Patients in quintile 1 of VASP analysis had a significantly lower risk of MACE as compared with those among the four higher quintiles (0 vs. 21, P |
| doi_str_mv | 10.1111/j.1538-7836.2007.02609.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68109881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68109881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4839-9812cfb1c3dfee58737dbba4ddfb0f052a81e92ea9a4bdd462fa2a584eed29c53</originalsourceid><addsrcrecordid>eNqNUc1u1DAQjhCIlsIrIJ-4bfBPsrEPHFBFaVElLm2vlmOPhVdJHDzJsnvrI_RReKY-CU53C1csWZ7RfN83M_6KgjBasnw-bkpWC7lqpFiXnNKmpHxNVbl7UZz-Lbx8jpUQJ8UbxA2lTNWcvi5OWFNJKWpxWvy-Mxhd6MwU0-P9A06hn3MCjow_IuY7pjhBGJ7TtM_VEAdiBtPtMSAZU4iJTJGMkOw8mQHijMTGFAeT9iQME6QtDE8kn5Gws92MSxY9GSNOuYMFNyfTkd5sMsK4LSQEYk1yIW4N2jxSJi4q-LZ45U2H8O74nhW3F19uzi9X19-_Xp1_vl7ZSgq1UpJx61tmhfMAtWxE49rWVM75lnpacyMZKA5Gmap1rlpzb7ipZQXguLK1OCs-HHTzeD9nwEn3AS103WFBvZaMKilZBsoD0KaImMDr_CN9Xl0zqhe39EYvRujFFL24pZ_c0rtMfX_sMbc9uH_Eoz0Z8OkA-BU62P-3sP52c7lE4g92S64O</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68109881</pqid></control><display><type>article</type><title>Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>BONELLO, L. ; PAGANELLI, F. ; ARPIN‐BORNET, M. ; AUQUIER, P. ; SAMPOL, J. ; DIGNAT‐GEORGE, F. ; BARRAGAN, P. ; CAMOIN‐JAU, L.</creator><creatorcontrib>BONELLO, L. ; PAGANELLI, F. ; ARPIN‐BORNET, M. ; AUQUIER, P. ; SAMPOL, J. ; DIGNAT‐GEORGE, F. ; BARRAGAN, P. ; CAMOIN‐JAU, L.</creatorcontrib><description>Background: Despite dual antiplatelet therapy, the rate of major adverse cardiovascular events (MACE) after percutaneous coronary angioplasty remains high. Studies have shown interindividual variations in response to clopidogrel. Furthermore, there is an apparent link between clinical outcomes and clopidogrel resistance. Objectives: To investigate the value of platelet reactivity index (PRI), assessed by vasodilator‐stimulated phosphoprotein (VASP) phosphorylation analysis, for predicting MACE after percutaneous coronary intervention (PCI) with stent implantation.Methods: A prospective monocentric study was performed on 144 patients undergoing PCI. PR was evaluated by VASP phosphorylation analysis 24 h after they received a 300‐mg loading dose of clopidogrel. MACE were recorded during a 6‐month follow‐up. Patients were divided into quintiles according to PRI, as assessed by VASP analysis. The receiver operating characteristic (ROC) curve served to determine the optimal cut‐off value of VASP analysis to detect MACE.Results: Of the 144 patients, 34% had stable angina pectoris, 40% silent ischemia, and 26% low‐risk non‐ST‐segment elevation acute coronary syndrome. During the follow‐up, 21 MACE were observed. Patients in quintile 1 of VASP analysis had a significantly lower risk of MACE as compared with those among the four higher quintiles (0 vs. 21, P < 0.01). ROC curve analysis of VASP showed an optimal cut‐off value of 50% PR to exclude MACE. The negative predictive value of the test was 100%.Conclusions: VASP phosphorylation analysis can evaluate the individual response to clopidogrel loading dose prior to PCI and predict postprocedural MACE.</description><identifier>ISSN: 1538-7933</identifier><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1111/j.1538-7836.2007.02609.x</identifier><identifier>PMID: 17488353</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Aged ; Angioplasty, Balloon, Coronary - methods ; biological resistance to clopidogrel ; Blood Platelets - metabolism ; Cardiovascular Diseases - prevention & control ; Cardiovascular Diseases - therapy ; Cell Adhesion Molecules - biosynthesis ; Cell Adhesion Molecules - chemistry ; coronary angioplasty ; Female ; Humans ; major adverse cardiovascular events ; Male ; Microfilament Proteins - biosynthesis ; Microfilament Proteins - chemistry ; Middle Aged ; Phosphoproteins - biosynthesis ; Phosphoproteins - chemistry ; Phosphorylation ; Platelet Aggregation Inhibitors - pharmacology ; platelet reactivity ; Predictive Value of Tests ; Prospective Studies ; Ticlopidine - analogs & derivatives ; Ticlopidine - pharmacology ; Vasodilator Agents - pharmacology ; vasodilator‐stimulated phosphoprotein phosphorylation</subject><ispartof>Journal of thrombosis and haemostasis, 2007-08, Vol.5 (8), p.1630-1636</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4839-9812cfb1c3dfee58737dbba4ddfb0f052a81e92ea9a4bdd462fa2a584eed29c53</citedby><cites>FETCH-LOGICAL-c4839-9812cfb1c3dfee58737dbba4ddfb0f052a81e92ea9a4bdd462fa2a584eed29c53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17488353$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BONELLO, L.</creatorcontrib><creatorcontrib>PAGANELLI, F.</creatorcontrib><creatorcontrib>ARPIN‐BORNET, M.</creatorcontrib><creatorcontrib>AUQUIER, P.</creatorcontrib><creatorcontrib>SAMPOL, J.</creatorcontrib><creatorcontrib>DIGNAT‐GEORGE, F.</creatorcontrib><creatorcontrib>BARRAGAN, P.</creatorcontrib><creatorcontrib>CAMOIN‐JAU, L.</creatorcontrib><title>Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>Background: Despite dual antiplatelet therapy, the rate of major adverse cardiovascular events (MACE) after percutaneous coronary angioplasty remains high. Studies have shown interindividual variations in response to clopidogrel. Furthermore, there is an apparent link between clinical outcomes and clopidogrel resistance. Objectives: To investigate the value of platelet reactivity index (PRI), assessed by vasodilator‐stimulated phosphoprotein (VASP) phosphorylation analysis, for predicting MACE after percutaneous coronary intervention (PCI) with stent implantation.Methods: A prospective monocentric study was performed on 144 patients undergoing PCI. PR was evaluated by VASP phosphorylation analysis 24 h after they received a 300‐mg loading dose of clopidogrel. MACE were recorded during a 6‐month follow‐up. Patients were divided into quintiles according to PRI, as assessed by VASP analysis. The receiver operating characteristic (ROC) curve served to determine the optimal cut‐off value of VASP analysis to detect MACE.Results: Of the 144 patients, 34% had stable angina pectoris, 40% silent ischemia, and 26% low‐risk non‐ST‐segment elevation acute coronary syndrome. During the follow‐up, 21 MACE were observed. Patients in quintile 1 of VASP analysis had a significantly lower risk of MACE as compared with those among the four higher quintiles (0 vs. 21, P < 0.01). ROC curve analysis of VASP showed an optimal cut‐off value of 50% PR to exclude MACE. The negative predictive value of the test was 100%.Conclusions: VASP phosphorylation analysis can evaluate the individual response to clopidogrel loading dose prior to PCI and predict postprocedural MACE.</description><subject>Aged</subject><subject>Angioplasty, Balloon, Coronary - methods</subject><subject>biological resistance to clopidogrel</subject><subject>Blood Platelets - metabolism</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Cardiovascular Diseases - therapy</subject><subject>Cell Adhesion Molecules - biosynthesis</subject><subject>Cell Adhesion Molecules - chemistry</subject><subject>coronary angioplasty</subject><subject>Female</subject><subject>Humans</subject><subject>major adverse cardiovascular events</subject><subject>Male</subject><subject>Microfilament Proteins - biosynthesis</subject><subject>Microfilament Proteins - chemistry</subject><subject>Middle Aged</subject><subject>Phosphoproteins - biosynthesis</subject><subject>Phosphoproteins - chemistry</subject><subject>Phosphorylation</subject><subject>Platelet Aggregation Inhibitors - pharmacology</subject><subject>platelet reactivity</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>Ticlopidine - analogs & derivatives</subject><subject>Ticlopidine - pharmacology</subject><subject>Vasodilator Agents - pharmacology</subject><subject>vasodilator‐stimulated phosphoprotein phosphorylation</subject><issn>1538-7933</issn><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUc1u1DAQjhCIlsIrIJ-4bfBPsrEPHFBFaVElLm2vlmOPhVdJHDzJsnvrI_RReKY-CU53C1csWZ7RfN83M_6KgjBasnw-bkpWC7lqpFiXnNKmpHxNVbl7UZz-Lbx8jpUQJ8UbxA2lTNWcvi5OWFNJKWpxWvy-Mxhd6MwU0-P9A06hn3MCjow_IuY7pjhBGJ7TtM_VEAdiBtPtMSAZU4iJTJGMkOw8mQHijMTGFAeT9iQME6QtDE8kn5Gws92MSxY9GSNOuYMFNyfTkd5sMsK4LSQEYk1yIW4N2jxSJi4q-LZ45U2H8O74nhW3F19uzi9X19-_Xp1_vl7ZSgq1UpJx61tmhfMAtWxE49rWVM75lnpacyMZKA5Gmap1rlpzb7ipZQXguLK1OCs-HHTzeD9nwEn3AS103WFBvZaMKilZBsoD0KaImMDr_CN9Xl0zqhe39EYvRujFFL24pZ_c0rtMfX_sMbc9uH_Eoz0Z8OkA-BU62P-3sP52c7lE4g92S64O</recordid><startdate>200708</startdate><enddate>200708</enddate><creator>BONELLO, L.</creator><creator>PAGANELLI, F.</creator><creator>ARPIN‐BORNET, M.</creator><creator>AUQUIER, P.</creator><creator>SAMPOL, J.</creator><creator>DIGNAT‐GEORGE, F.</creator><creator>BARRAGAN, P.</creator><creator>CAMOIN‐JAU, L.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200708</creationdate><title>Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events</title><author>BONELLO, L. ; PAGANELLI, F. ; ARPIN‐BORNET, M. ; AUQUIER, P. ; SAMPOL, J. ; DIGNAT‐GEORGE, F. ; BARRAGAN, P. ; CAMOIN‐JAU, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4839-9812cfb1c3dfee58737dbba4ddfb0f052a81e92ea9a4bdd462fa2a584eed29c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Angioplasty, Balloon, Coronary - methods</topic><topic>biological resistance to clopidogrel</topic><topic>Blood Platelets - metabolism</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Cardiovascular Diseases - therapy</topic><topic>Cell Adhesion Molecules - biosynthesis</topic><topic>Cell Adhesion Molecules - chemistry</topic><topic>coronary angioplasty</topic><topic>Female</topic><topic>Humans</topic><topic>major adverse cardiovascular events</topic><topic>Male</topic><topic>Microfilament Proteins - biosynthesis</topic><topic>Microfilament Proteins - chemistry</topic><topic>Middle Aged</topic><topic>Phosphoproteins - biosynthesis</topic><topic>Phosphoproteins - chemistry</topic><topic>Phosphorylation</topic><topic>Platelet Aggregation Inhibitors - pharmacology</topic><topic>platelet reactivity</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>Ticlopidine - analogs & derivatives</topic><topic>Ticlopidine - pharmacology</topic><topic>Vasodilator Agents - pharmacology</topic><topic>vasodilator‐stimulated phosphoprotein phosphorylation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BONELLO, L.</creatorcontrib><creatorcontrib>PAGANELLI, F.</creatorcontrib><creatorcontrib>ARPIN‐BORNET, M.</creatorcontrib><creatorcontrib>AUQUIER, P.</creatorcontrib><creatorcontrib>SAMPOL, J.</creatorcontrib><creatorcontrib>DIGNAT‐GEORGE, F.</creatorcontrib><creatorcontrib>BARRAGAN, P.</creatorcontrib><creatorcontrib>CAMOIN‐JAU, L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BONELLO, L.</au><au>PAGANELLI, F.</au><au>ARPIN‐BORNET, M.</au><au>AUQUIER, P.</au><au>SAMPOL, J.</au><au>DIGNAT‐GEORGE, F.</au><au>BARRAGAN, P.</au><au>CAMOIN‐JAU, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2007-08</date><risdate>2007</risdate><volume>5</volume><issue>8</issue><spage>1630</spage><epage>1636</epage><pages>1630-1636</pages><issn>1538-7933</issn><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract>Background: Despite dual antiplatelet therapy, the rate of major adverse cardiovascular events (MACE) after percutaneous coronary angioplasty remains high. Studies have shown interindividual variations in response to clopidogrel. Furthermore, there is an apparent link between clinical outcomes and clopidogrel resistance. Objectives: To investigate the value of platelet reactivity index (PRI), assessed by vasodilator‐stimulated phosphoprotein (VASP) phosphorylation analysis, for predicting MACE after percutaneous coronary intervention (PCI) with stent implantation.Methods: A prospective monocentric study was performed on 144 patients undergoing PCI. PR was evaluated by VASP phosphorylation analysis 24 h after they received a 300‐mg loading dose of clopidogrel. MACE were recorded during a 6‐month follow‐up. Patients were divided into quintiles according to PRI, as assessed by VASP analysis. The receiver operating characteristic (ROC) curve served to determine the optimal cut‐off value of VASP analysis to detect MACE.Results: Of the 144 patients, 34% had stable angina pectoris, 40% silent ischemia, and 26% low‐risk non‐ST‐segment elevation acute coronary syndrome. During the follow‐up, 21 MACE were observed. Patients in quintile 1 of VASP analysis had a significantly lower risk of MACE as compared with those among the four higher quintiles (0 vs. 21, P < 0.01). ROC curve analysis of VASP showed an optimal cut‐off value of 50% PR to exclude MACE. The negative predictive value of the test was 100%.Conclusions: VASP phosphorylation analysis can evaluate the individual response to clopidogrel loading dose prior to PCI and predict postprocedural MACE.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17488353</pmid><doi>10.1111/j.1538-7836.2007.02609.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1538-7933 |
| ispartof | Journal of thrombosis and haemostasis, 2007-08, Vol.5 (8), p.1630-1636 |
| issn | 1538-7933 1538-7836 1538-7836 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68109881 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Aged Angioplasty, Balloon, Coronary - methods biological resistance to clopidogrel Blood Platelets - metabolism Cardiovascular Diseases - prevention & control Cardiovascular Diseases - therapy Cell Adhesion Molecules - biosynthesis Cell Adhesion Molecules - chemistry coronary angioplasty Female Humans major adverse cardiovascular events Male Microfilament Proteins - biosynthesis Microfilament Proteins - chemistry Middle Aged Phosphoproteins - biosynthesis Phosphoproteins - chemistry Phosphorylation Platelet Aggregation Inhibitors - pharmacology platelet reactivity Predictive Value of Tests Prospective Studies Ticlopidine - analogs & derivatives Ticlopidine - pharmacology Vasodilator Agents - pharmacology vasodilator‐stimulated phosphoprotein phosphorylation |
| title | Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A54%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vasodilator%E2%80%90stimulated%20phosphoprotein%20phosphorylation%20analysis%20prior%20to%20percutaneous%20coronary%20intervention%20for%20exclusion%20of%20postprocedural%20major%20adverse%20cardiovascular%20events&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=BONELLO,%20L.&rft.date=2007-08&rft.volume=5&rft.issue=8&rft.spage=1630&rft.epage=1636&rft.pages=1630-1636&rft.issn=1538-7933&rft.eissn=1538-7836&rft_id=info:doi/10.1111/j.1538-7836.2007.02609.x&rft_dat=%3Cproquest_cross%3E68109881%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68109881&rft_id=info:pmid/17488353&rfr_iscdi=true |